Biotech restructurings show signs of slowing

At least 22 companies have disclosed restructurings in the past two months, as large players push for efficiency, data readouts upend development plans, and commercial strategies evolve. The restructuring activity marks a reduction from the depths of summer, when almost as many companies restructured in the first two weeks of August alone. 

After half a dozen large-scale restructurings by major pharmas in the past two years, culminating this spring with Bristol Myers Squibb Co. (NYSE:BMY),  Bayer AG (Xetra:BAYN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) disclosing that they would respectively cut 2,220, 1,500 and 1,185 jobs, the number of pharma layoffs has slowed since mid-August...